Western Therapeutics Says Observation Phase Completed in Global Trial of Fuchs Drug K-321
MT Newswires Live
Nov 21
D. Western Therapeutics Institute (TYO:4576) said the observation period has finished in one of two global Phase III trials of K-321, its investigational treatment for Fuchs endothelial corneal dystrophy, according to a Friday filing on the Tokyo Stock Exchange.
The study, led by licensee Kowa, is testing the efficacy and safety of K-321 versus placebo when used as an eye drop after simultaneous Descemet's membrane stripping and cataract surgery.
Fuchs endothelial corneal dystrophy progressively damages the corneal endothelium, and corneal transplantation remains the main treatment for severe cases. Western Therapeutics and Kowa said they aim to develop K-321 as a new therapeutic option.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.